Hatfield v. Collins

Plain English (For Everyone)

A recent court ruling decided that a method for identifying genetic sequences is not patentable. The court said that the basic idea of finding and comparing these sequences is a natural phenomenon and an abstract concept, and the steps involved weren't innovative enough to make it a new invention. This means companies can't get patents on fundamental biological discovery methods.

For Legal Practitioners

The Federal Circuit affirmed the PTAB's § 101 rejection of claims directed to a method for detecting and quantifying nucleic acid sequences. The court held that the claims were directed to a natural phenomenon and an abstract idea, and the additional steps did not amount to 'significantly more' as they were routine and conventional. This reinforces the strict application of the Alice/Mayo framework to diagnostic and method-of-use claims involving natural phenomena.

For Law Students

In Hatfield v. Collins, the Federal Circuit applied the Alice/Mayo test to find claims for detecting and quantifying nucleic acid sequences ineligible under § 101. The court determined the claims were directed to a natural phenomenon and an abstract idea, and the recited steps did not add 'significantly more' because they were conventional. This case highlights the importance of demonstrating inventive concepts beyond the mere application of natural laws or abstract ideas.

Newsroom Summary

A federal court has ruled that a method for detecting and analyzing genetic sequences cannot be patented. The court found the invention too similar to natural processes and abstract concepts, lacking sufficient innovation to qualify for patent protection. This decision impacts the patentability of methods involving biological discoveries.

Standard of Review

De novo review. The Federal Circuit reviews the Patent Trial and Appeal Board's (PTAB) determination of patent eligibility under 35 U.S.C. § 101 without deference.

Procedural Posture

The case reached the Federal Circuit on appeal from a final decision of the Patent Trial and Appeal Board (PTAB) finding the patent claims ineligible under 35 U.S.C. § 101.

Burden of Proof

The burden of proof is on the patent applicant to show that their claims are patent-eligible. The standard is whether the claims are directed to an abstract idea or natural phenomenon without significantly more.

Legal Tests Applied

Statutory References

Key Legal Definitions

Rule Statements

The claims are directed to the natural phenomenon of detecting nucleic acid sequences and the abstract idea of comparing those sequences.

The claims do not add 'significantly more' to transform the patent eligibility of the claims.

The additional steps recited in the claims are routine and conventional activities that do not transform the claims into a patent-eligible application.

Remedies

Affirmed the PTAB's decision of patent ineligibility.

Scenario: You are a biotech startup developing a new diagnostic test that uses a known method to detect a specific gene mutation.

Your Rights: You may not be able to patent the core method of detection if it's considered a natural phenomenon or abstract idea without significant additional inventive steps.

What To Do: Focus patent claims on novel aspects of your diagnostic test, such as specific reagents, unique analytical steps, or a novel combination of elements that go beyond the basic detection method.

Scenario: You are a researcher who has discovered a new way to compare DNA sequences that is more efficient than existing methods.

Your Rights: Your discovery of a more efficient comparison method might be considered an abstract idea and thus not patentable on its own.

What To Do: Seek patent protection for specific technological implementations or improvements that embody your discovery, rather than the abstract concept of comparison itself.

Is it legal to patent a method for detecting a specific disease marker in blood?

Depends. If the method relies solely on identifying a natural marker and uses routine steps, it may be deemed ineligible under 35 U.S.C. § 101, as seen in Hatfield v. Collins. However, if the method includes significant inventive steps or a specific technological application beyond the natural phenomenon, it might be patentable.

Applies to patent law in the United States.

For Biotechnology and pharmaceutical companies

The ruling makes it more difficult to obtain patents on methods that involve detecting or analyzing natural biological sequences or processes. Companies may need to focus on patenting specific technological applications or novel combinations of elements rather than the underlying scientific discovery.

For Diagnostic test developers

Developers of diagnostic tests that rely on identifying natural phenomena (like genetic sequences) may find their core methods unpatentable. They will need to ensure their claims include 'significantly more' inventive features to meet patent eligibility requirements.

For Academic researchers

The ruling reinforces that fundamental scientific discoveries and abstract methods of analysis are generally not patentable. Researchers may find it easier to publish and share findings related to natural phenomena without patent barriers, but commercialization of such methods will require further inventive steps.

Q: What is Hatfield v. Collins about?

Hatfield v. Collins is a case decided by Federal Circuit on May 2, 2025.

Q: What court decided Hatfield v. Collins?

Hatfield v. Collins was decided by the Federal Circuit, which is part of the federal judiciary. This is a federal appellate court.

Q: When was Hatfield v. Collins decided?

Hatfield v. Collins was decided on May 2, 2025.

Q: What is the citation for Hatfield v. Collins?

The citation for Hatfield v. Collins is 135 F.4th 1362. Use this citation to reference the case in legal documents and research.

Q: What was the main issue in Hatfield v. Collins?

The main issue was whether a method for detecting and quantifying nucleic acid sequences was patent-eligible under 35 U.S.C. § 101. The Federal Circuit found it was not.

Q: What is 35 U.S.C. § 101?

35 U.S.C. § 101 defines the categories of inventions that are eligible for patent protection, including processes, machines, manufactures, and compositions of matter.

Q: Is Hatfield v. Collins published?

Hatfield v. Collins is a published, precedential opinion. Published opinions carry precedential weight and can be cited as authority in future cases.

Q: What was the ruling in Hatfield v. Collins?

The court ruled in favor of the defendant in Hatfield v. Collins. Key holdings: The court held that claims directed to a method for detecting and quantifying nucleic acid sequences are ineligible under 35 U.S.C. § 101 because they are directed to a natural phenomenon and an abstract idea.; The court applied the Alice/Mayo two-step framework, finding that the claims were first directed to the natural phenomenon of detecting nucleic acid sequences and the abstract idea of comparing those sequences.; The court determined that the claims did not provide significantly more than the natural phenomenon and abstract idea, as the steps involved were conventional and routine in the field of nucleic acid detection.; The court rejected the patentee's argument that the claims were transformative, finding that the claimed method did not add enough inventive concept to overcome the § 101 ineligibility.; The court affirmed the PTAB's decision to invalidate the claims based on the § 101 analysis..

Q: Why is Hatfield v. Collins important?

Hatfield v. Collins has an impact score of 65/100, indicating significant legal impact. This decision underscores the ongoing challenges in patenting diagnostic methods and natural phenomena under 35 U.S.C. § 101. It signals that claims directed to detecting natural laws or abstract ideas, even with conventional steps, are likely to be found ineligible, requiring a higher bar for demonstrating patentable inventiveness in such fields.

Q: What precedent does Hatfield v. Collins set?

Hatfield v. Collins established the following key holdings: (1) The court held that claims directed to a method for detecting and quantifying nucleic acid sequences are ineligible under 35 U.S.C. § 101 because they are directed to a natural phenomenon and an abstract idea. (2) The court applied the Alice/Mayo two-step framework, finding that the claims were first directed to the natural phenomenon of detecting nucleic acid sequences and the abstract idea of comparing those sequences. (3) The court determined that the claims did not provide significantly more than the natural phenomenon and abstract idea, as the steps involved were conventional and routine in the field of nucleic acid detection. (4) The court rejected the patentee's argument that the claims were transformative, finding that the claimed method did not add enough inventive concept to overcome the § 101 ineligibility. (5) The court affirmed the PTAB's decision to invalidate the claims based on the § 101 analysis.

Q: What are the key holdings in Hatfield v. Collins?

1. The court held that claims directed to a method for detecting and quantifying nucleic acid sequences are ineligible under 35 U.S.C. § 101 because they are directed to a natural phenomenon and an abstract idea. 2. The court applied the Alice/Mayo two-step framework, finding that the claims were first directed to the natural phenomenon of detecting nucleic acid sequences and the abstract idea of comparing those sequences. 3. The court determined that the claims did not provide significantly more than the natural phenomenon and abstract idea, as the steps involved were conventional and routine in the field of nucleic acid detection. 4. The court rejected the patentee's argument that the claims were transformative, finding that the claimed method did not add enough inventive concept to overcome the § 101 ineligibility. 5. The court affirmed the PTAB's decision to invalidate the claims based on the § 101 analysis.

Q: What cases are related to Hatfield v. Collins?

Precedent cases cited or related to Hatfield v. Collins: Alice Corp. v. CLS Bank Int'l, 573 U.S. 208 (2014); Mayo Collaborative Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012).

Q: Why did the court rule the method ineligible?

The court determined the claims were directed to a natural phenomenon (detecting nucleic acid sequences) and an abstract idea (comparing them), and did not add 'significantly more' to transform them into a patent-eligible application.

Q: What does 'significantly more' mean in patent law?

'Significantly more' refers to additional elements in a claim that transform it into a patent-eligible application when considered alongside a judicial exception like a natural phenomenon or abstract idea. Routine or conventional steps do not qualify.

Q: Did the court consider the method to be a natural phenomenon or an abstract idea?

The court considered the claims to be directed to both the natural phenomenon of detecting nucleic acid sequences and the abstract idea of comparing them.

Q: What is the Alice/Mayo test?

It's a two-step test used to determine patent eligibility: first, is the claim directed to a judicial exception (law of nature, natural phenomenon, abstract idea)? Second, if so, does it include significantly more than the exception itself?

Q: Can you patent a discovery of a natural law?

Generally, no. Discoveries of natural laws, natural phenomena, and abstract ideas are not patentable subject matter under 35 U.S.C. § 101. Patents must be for an application of these discoveries.

Q: How does Hatfield v. Collins affect me?

This decision underscores the ongoing challenges in patenting diagnostic methods and natural phenomena under 35 U.S.C. § 101. It signals that claims directed to detecting natural laws or abstract ideas, even with conventional steps, are likely to be found ineligible, requiring a higher bar for demonstrating patentable inventiveness in such fields. As a decision from a federal appellate court, its reach is national. This case is moderate in legal complexity to understand.

Q: What are the implications for diagnostic tests?

Diagnostic tests that rely on identifying natural phenomena or abstract diagnostic methods may face challenges in patent eligibility unless they include significant inventive steps beyond the mere detection or comparison.

Q: What should inventors do to ensure their claims are patent-eligible?

Inventors should focus on claims that recite specific technological improvements, novel applications, or combinations of elements that go beyond the natural phenomenon or abstract idea itself.

Q: How does this ruling affect companies developing genetic analysis tools?

Companies may find it harder to patent the core methods of genetic analysis if they are considered natural phenomena or abstract ideas. They should focus on patenting specific technological implementations or unique analytical processes.

Q: Is this ruling new or a continuation of existing patent law?

This ruling is a continuation and application of existing patent eligibility jurisprudence, particularly the Alice/Mayo test, as applied to methods involving natural phenomena and abstract ideas.

Q: What was the docket number in Hatfield v. Collins?

The docket number for Hatfield v. Collins is 23-2280. This identifier is used to track the case through the court system.

Q: Can Hatfield v. Collins be appealed?

Potentially — decisions from federal appellate courts can be appealed to the Supreme Court of the United States via a petition for certiorari, though the Court accepts very few cases.

Q: What was the prior decision that led to this appeal?

The Federal Circuit reviewed a decision by the Patent Trial and Appeal Board (PTAB) which had found the patent claims ineligible under 35 U.S.C. § 101.

Q: What is the standard of review for patent eligibility decisions from the PTAB?

The Federal Circuit reviews decisions on patent eligibility under 35 U.S.C. § 101 de novo, meaning without deference to the PTAB's findings.